Planned international multicenter, open-label, randomized modular phase III successor trial to HR2 to improve patient outcomes and decrease toxicities for patients with front-line high-risk neuroblastoma building on results from HR2 and pilot trials.

The main objective of the HR-NBL1 trial is to correlate clinical, therapeutic and molecular biological features with Event Free Survival (EFS).

SIOPREN-R-NET is an accessible central database and communication system to allow clinical trial management with remote data entry on electronic case report forms (eCRFs), electronic data capture, remote randomisation and the distribution of information on trial progress.

BEACON2 is a platform multi-arm multi-stage (MAMS) randomised phase I/phase II, open-label, international trial for participants with relapsed neuroblastoma.

This study aims to improve the outcome for patients with newly diagnosed high-risk neuroblastoma.

This study aims to improve the outcome for patients with newly diagnosed low and intermediate-risk neuroblastoma.

This study aims to improve the outcome for patients with high risk neuroblastoma which is refractory to induction chemotherapy

This study aims to improve the outcome of children with relapsed or refractory neuroblastoma.

This study aims to collect information about the outcome of patients with neuroblastoma and spinal cord compression.

This is a phase I trial investigating combining 131-I mIBG therapy, anti-PD-1 antibody (Nivolumab) and anti-GD2 antibody (dinutuximab beta) in children with relapsed or refractory neuroblastoma.

This study aims to improve the outcome of patients with relapsed or refractory neuroblastoma.

This study aims to improve the outcome of patients with low and intermediate risk neuroblastoma. The study is evaluating the use RNA expression array based treatment stratification algorithm.

The prognosis for children with relapsed or refractory high-risk neuroblastoma is dismal with very few survivors. As neuroblastoma is known to be a relatively radiosensitive tumor, targeted intravenous radiotherapy is an attractive treatment option and 131I-mIBG treatment has been used in a relapse setting, since the 1980’s.